Abstract
The formal C-20 methylation of 1,25-dihydroxy vitamin D3 (calcitriol) and bridging of two methyl groups produces spiro[cyclopropane-1, 20-calcitriol], colloquially referred to as C-20 cyclopropylcalcitriol, which is much more active in MLR for suppression of interferon-γ release than calcitriol, and hypercalcemia in mice is elicited at a ten-fold lower dose when compared to calcitriol. Introduction of the Δ16,17-double bond, modification of the side chain by 23- unsaturation and replacement of the methyl groups at C-26 and C-27 with trifluoromethyl moieties create a highly active series of vitamin D analogs. As previously observed in the calcitriol series, the presence of the C-16 double bond in the cyclopropyl analogs also arrests metabolic side-chain oxidation in the at the C-24 oxo level in UMR 106 cells. The enhanced biological activity is ascribed, at least in part, to the improved resistance toward metabolic degradation.
Keywords: hydrogenation, Transactivation, Prostate tumor, UMR 106 cells, 20-cyclopropyl analogs
Current Topics in Medicinal Chemistry
Title: C-20 Cyclopropyl Vitamin D3 Analogs
Volume: 6 Issue: 12
Author(s): Milan R. Uskokovic, Percy Manchand, Stanislaw Marczak, Hubert Maehr, Pawel Jankowski, Luciano Adorini and G. Satyanarayana Reddy
Affiliation:
Keywords: hydrogenation, Transactivation, Prostate tumor, UMR 106 cells, 20-cyclopropyl analogs
Abstract: The formal C-20 methylation of 1,25-dihydroxy vitamin D3 (calcitriol) and bridging of two methyl groups produces spiro[cyclopropane-1, 20-calcitriol], colloquially referred to as C-20 cyclopropylcalcitriol, which is much more active in MLR for suppression of interferon-γ release than calcitriol, and hypercalcemia in mice is elicited at a ten-fold lower dose when compared to calcitriol. Introduction of the Δ16,17-double bond, modification of the side chain by 23- unsaturation and replacement of the methyl groups at C-26 and C-27 with trifluoromethyl moieties create a highly active series of vitamin D analogs. As previously observed in the calcitriol series, the presence of the C-16 double bond in the cyclopropyl analogs also arrests metabolic side-chain oxidation in the at the C-24 oxo level in UMR 106 cells. The enhanced biological activity is ascribed, at least in part, to the improved resistance toward metabolic degradation.
Export Options
About this article
Cite this article as:
Uskokovic R. Milan, Manchand Percy, Marczak Stanislaw, Maehr Hubert, Jankowski Pawel, Adorini Luciano and Reddy G. Satyanarayana, C-20 Cyclopropyl Vitamin D3 Analogs, Current Topics in Medicinal Chemistry 2006; 6 (12) . https://dx.doi.org/10.2174/156802606777864962
DOI https://dx.doi.org/10.2174/156802606777864962 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Retinoblastoma Protein in Osteoblast Differentiation and Osteosarcoma
Current Molecular Medicine Recent Advances in Thymidine Kinase 2 (TK2) Inhibitors and New Perspectives for Potential Applications
Current Pharmaceutical Design Bioavailability and Pharmacokinetics of Genistein: Mechanistic Studies on its ADME
Anti-Cancer Agents in Medicinal Chemistry KiSS1-Induced GPR54 Signaling Inhibits Breast Cancer Cell Migration and Epithelial-Mesenchymal Transition via Protein Kinase D1
Current Molecular Medicine PEDF & Stem Cells: Niche vs. Nurture
Current Drug Delivery Repurposing of Metformin for Cancer Therapy: Updated Patent and Literature Review
Recent Patents on Anti-Cancer Drug Discovery Nanomedicine to Overcome Cancer Multidrug Resistance
Current Drug Metabolism Targeting Transcription Factors for Cancer Gene Therapy
Current Gene Therapy Proteomic Profiling of a Biomimetic Drug Delivery Platform
Current Drug Targets Imaging Virus-Associated Cancer
Current Pharmaceutical Design The Role of Connexins in Carcinogenesis: Review of Current Knowledge
Current Signal Transduction Therapy Therapies of Hematological Malignancies: An Overview of the Potential Targets and Their Inhibitors
Current Chemical Biology Pharmacotherapies to Manage Bone Loss-Associated Diseases: A Quest for the Perfect Benefit-to-Risk Ratio
Current Medicinal Chemistry Patenting Networking and Knowledge Translation in Liposomes for Cancer Therapy
Recent Patents on Nanomedicine New Insights Toward Nanostructured Drug Delivery of Plant-Derived Polyphenol Compounds: Cancer Treatment and Gene Expression Profiles
Current Cancer Drug Targets Dihydrotestosterone Induces Chemo-Resistance of Triple-Negative Breast MDA-MB-231 Cancer Cells Towards Doxorubicin Independent of ABCG2 and miR-328-3p
Current Molecular Pharmacology Functional Interplay between RNA-Binding Protein HuR and microRNAs
Current Protein & Peptide Science Drug Therapy of Neuropathic Pain: Current Developments and Future Perspectives
Current Drug Targets Osteoprotegerin A Physiological and Pharmacological Inhibitor of Bone Resorption.
Current Pharmaceutical Design Distinctive Cellular Roles for Novel Protein Kinase C Isoenzymes
Current Pharmaceutical Design